ERBB2 and neoplasm: A HER2-targeted ADC carrying two cytotoxic agents demonstrated superior efficacy and survival benefits compared to single-payload ADCs in resistant, heterogeneous tumor models, with minimal toxicity and favorable pharmacokinetics [58].